<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814043</url>
  </required_header>
  <id_info>
    <org_study_id>B2020-411</org_study_id>
    <nct_id>NCT04814043</nct_id>
  </id_info>
  <brief_title>PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial</brief_title>
  <acronym>PLATIC</acronym>
  <official_title>Systemic PD-1 Antibody (Sintilimab) and Lenvatinib Plus Transarterial Chemoembolization and FOLFOX-based Chemotherapy Infusion for Potential Resectable HCC: a Single-arm, Phase 2 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world.&#xD;
      Hepatic resection or liver transplantation is the radical method to cure the disease.&#xD;
      However, less than 20% of newly diagnosed patients can undergo radical resection. Our latest&#xD;
      study showed that 48% potentially resectable HCC received hepatectomy after transarterial&#xD;
      chemoembolization plus FOLFOX-based chemotherapy infusion (TACE-HAIC) treatment. Recently,&#xD;
      several clinical trials (LEAP-002) showed that PD-1 antibody and Lenvatinib had an ORR of 36%&#xD;
      for advanced patients. The combination of TACE-HAIC with PD-1 antibody and lenvatinib,&#xD;
      theoretically can significantly decrease the tumor burden and increase the hepatectomy rate.&#xD;
      However, this hasn't been verified in clinical application. To identify a more effective and&#xD;
      safety way for treating potentially resectable HCC patients, this study is designed to&#xD;
      investigate TACE-HAIC plus PD-1 antibody and Lenvatinib will increase the resection rate for&#xD;
      those patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>systemic PD-1 antibody and lenvatinib plus TACE-HAIC for potential resectable HCC</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>conversion rate to resection</measure>
    <time_frame>12 month</time_frame>
    <description>The conversion rate to resection among all the enrolled patients</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>PD-1 antibody and lenvatinib plus TACE-HAIC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 inhibitor</intervention_name>
    <description>systemic PD-1 antibody (Sintilimab) and lenvatinib plus transarterial chemobolization and FOLFOX-based chemotherapy infusion</description>
    <arm_group_label>PD-1 antibody and lenvatinib plus TACE-HAIC</arm_group_label>
    <other_name>lenvatinib</other_name>
    <other_name>TACE-HAIC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed as potentially resectable with consensus by the panel of liver surgeons&#xD;
&#xD;
          -  stage BCLC A/B/C, without extra-hepatic involvement&#xD;
&#xD;
          -  No previous anti-HCC treatment&#xD;
&#xD;
          -  Eastern Co-operative Group performance status 2 or less&#xD;
&#xD;
          -  Liver function: Child's A or B (score &lt; 7)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or&#xD;
             hepatic encephalopathy&#xD;
&#xD;
               -  underlying serve cardiac or renal diseases Known or suspected allergy to the&#xD;
                  investigational agent or any agent given in association with this trial&#xD;
&#xD;
               -  Patients ineligible for hepatic artery embolization, or PD-1 antibody&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunfei Yuan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiliang Qiu</last_name>
    <phone>+862087343114</phone>
    <email>qiujl@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiliang Qiu</last_name>
      <phone>+862087342651</phone>
      <email>qiujl@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yunfei Yuan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

